B. Riley Securities Maintains Buy on Longboard Pharmaceuticals, Raises Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has maintained its Buy rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and raised the price target from $30 to $36.
June 11, 2024 | 6:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B. Riley Securities has maintained its Buy rating on Longboard Pharmaceuticals and increased the price target from $30 to $36, indicating strong confidence in the company's future performance.
The raised price target and maintained Buy rating from B. Riley Securities suggest positive sentiment and confidence in Longboard Pharmaceuticals' future performance, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100